JK-1201I
Phase 3Small molecule
JK-1201I is one of 136 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
3
Indications
5
Total Trials
3
Active Trials
135
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1JK-1201I
JJenKem Technology Co., Ltd.
Phase 3
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Duragesic
CCephalon
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer1 trial
Glioblastoma Multiforme1 trial
Malignant Solid Tumor1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JK-1201I. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- JJenKem Technology Co., Ltd.